Objective-To validate a simple noninvasive method with serial creatine kinase measurements for diagnosis of early patency of the infarct related artery after thrombolytic treatment with streptokinase. To investigate the relation between early patency of the infarct related artery and prognosis. Design-Patients under 76 years of age and seen within six hours of the start of prolonged chest pain and ST segment elevation were treated with streptokinase (1x5 x 106U) intravenously over 30-60 minutes. Blood for measurement of total creatine kinase activity was taken at baseline and at 1, 2, 3, 4, 8, 12, 16, 20 , and 24 hours after starting treatment. The rise in enzyme activity at each time from baseline was expressed as a proportion of the total rise from baseline to peak. Patients-Patients studied were in the following groups: (a) Sixty patients took part in a validation study with angiographic determination of patency of the infarct related coronary artery at 2*6 (0.3) hours (mean (SD)) after starting streptokinase. (b) A further 258 patients did not have early arteriography, but data were added to those from the 60 validation patients to find the relation between enzymatically determined early patency of the infarct related artery and 30 day mortality. (c) A further subset of 232 patients with first infarctions (including patients from groups (a) and (b) had angiocardiography at three weeks after infarction, and data were used to investigate the relation between early patency of the infarct related artery and left ventricular function. Main outcome measures-Normalised rate of rise of creatine kinase activity at three hours after starting streptokinase in relation to angiographic patency of the infarct related coronary artery at 2-5 hours; 30 day cardiac mortality; and left ventricular function at three weeks in survivors of first infarction. Results-In the validation study, a rise in three hour creatine kinase activity of >20% of peak occurred in 34137 patients with initially patent infarct related coronary arteries (sensitivity 92%), and a rise to <20% of peak occurred in 21/23 patients with initially occluded arteries (specificity 91%). In the prognostic study, 30 day mortality was 2*1% in the 191 patients with three hour creatine kinase >200/o of peak and 8-7% in the 127 patients with three hour creatine kinase < 20% of peak (p < 0.01). Angiocardiography in three week survivors of anterior infarction (n = 95) showed better left ventricular function when three hour creatine kinase was >20% than when it was <20% of peak (mean (SEM) end systolic volume 71 (5) v 96 (9) ml, p <0-02; ejection fraction 56% (2%) v 51% (2%), NS).
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Conclusion-Non-invasive determination of early patency of the infarct related artery by the normalised rate of rise of creatine kinase activity at three hours seems to be reliable, and may be prognostically important and of value for use in clinical trials.
(Br Heart J 1993;69:485-491) Successful thrombolytic treatment for acute myocardial infarction depends on recanalisation of occluded coronary arteries, and the standard technique for diagnosis of reperfusion has been coronary arteriography.12 Arteriography however, is invasive, expensive, and measures arterial patency at only one time. A simple reliable method for non-invasive diagnosis, if it could be shown to be prognostically meaningful, would be valuable for large scale use in therapeutic trials.
In our study we compared serial measurements of creatine kinase activity with arteriographic assessment of patency of the infarct related artery in 60 patients, paying particular attention to timing for our assessment of patency. We chose 2 5 hours rather than the more conventional 90 minutes after the start of streptokinase infusion for coronary arteriography (because of the known slower action of streptokinase than tissue plasminogen activator (alteplase)'5) and we selected three hours after thrombolytic treatment for measurement of enzyme activity (because of an expected time lag between recanalisation and enzyme washout). A concomitant study to assess the effect of intracoronary alteplase for patients in whom intravenous streptokinase had failed to restore arterial patency6 also allowed us to assess the rate of rise of creatine kinase activity in relation to a known time of reperfusion.
We also investigated the relation between enzymically determined patency of the infarct Norris, White, Cross, Woo, Elliott, Twigden, Williams, 3'ohnson related artery, 30 day mortality, and left ventricular functional impairment in a larger group of 318 patients.
Patients and methods
The study was divided into two parts that ran concurrently, a validation study and a prognostic study. Criteria for enrollment included age < 76 years, typical chest pain starting within the previous six (mean 3 0, range 0 5-6) hours, and ST segment elevation in at least two leads of the electrocardiogram of > 
Results

VALIDATION STUDY
Arteriographic and clinicalfindings Because of other demands on the catheterisation laboratory, it was not always possible to image the infarct related artery precisely at 2i5 hours after starting thrombolytic treatment; in the event the artery was imaged at (mean (SD)) 2-6 (0-3) hours after starting treatment.
The infarct related artery was the left anterior descending in 31 patients, the right coronary in 26, and the left circumflex in three. It was patent (TIMI 3, 35; TIMI 2, two) in 37 (62%) of the 60 patients at the first injection of contrast (group 1), and in a further 14 (23%) either at a subsequent injection or after infusion of alteplase at five to 60 (mean 25) minutes after the first series of injections (group 2). The artery was not patent at any time in nine (15%) of the patients (group 3). No serious bleeding or other untoward event occurred as a result of arteriography.
The group 1 patients with early arterial patency included six patients (group la) in whom creatine kinase activity did not rise above 600 IU/1, twice the upper normal value for our laboratory. These patients all had severe prolonged chest pain and ST segment elevation, and were indistinguishable clinically at the time of admission from patients in whom enzyme activity rose to conventionally diagnostic values. Five of the six patients had stenoses of the infarct related coronary artery (with subtotal occlusion and TIMI 2 flow in one), and one had angiographically normal coronary arteries. Five of the six had normal left ventricular function at ventriculography whereas the sixth patient had segmental hypokinesis. Changes in the T wave without pathological Q waves evolved in five patients and in one patient the electrocardiogram reverted to normal after thrombolytic treatment. Four of the six group la patients in whom enzyme activity did not rise above twice the upper limit of normal also showed a rise that occurred through the normal range to a peak within eight hours of thrombolysis, followed by a fall to resting values of 100-250 IU/l by 24 hours. The peak activity exceeded twice the baseline in three of these four patients and was slightly less than twice the baseline in the fourth. The remaining two patients showed a peak in the baseline specimen that fell gradually over [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hours to resting values of less than half the baseline. Time after thrombolysis (h) Figure 1 shows normalised values for the three groups of patients from one to 12 hours after thrombolytic treatment. Significant differences in proportions of the enzyme occurred between group 1 and 2 patients at one, two, and three hours after treatment and between group 2 and 3 patients at four, eight, and 12 hours after treatment. Figure 2 shows the proportion of peak creatine kinase activity in the three hour specimen from patients in groups 1, 2, and 3. Good discrimination is shown, 34 (92%) of the 37 group 1 patients, including all six group la patients with a non-diagnostic enzyme rise, showed a three hour creatine kinase of > 20% of peak. Three hour creatine kinase was < 20% in 21 (91%) of the 23 patients in groups 2 and 3 who had coronary occlusion at first imaging by coronary arteriography.
Relation between time of restoration of arterial patency and enzyme washout Of the 14 group 2 patients who had restoration of patency of the infarct released artery either by contrast or by intracoronary infusion of alteplase, patency occurred before taking the four hour blood specimen in 11. To examine the rate of enzyme release and the lag phase with restoration of patency, we plotted the three and four hour values for creatine kinase activity as a percentage of the peak for these 11 patients (fig 3) , comparing them with nine patients seven group 3, two group 2) in whom four hour enzyme activities were available and the artery was known to have remained occluded at that time. Also, fig 3 shows the three and four hour values for the three patients with early patency who had a three-hour washout of < 20% (shown in fig 2) .
There was a much more rapid rise in activity as a percentage of the peak in patients with restored patency over this one hour period (mean 20% rise, range 7%-36%) than in patients with sustained occlusion (mean 4% rise, range 0%-8%). The three patients who had early patency but a low three-hour enzyme washout also showed a rapid washout between three and four hours (mean 29%, range 25%-33%) similar to that shown by patients with restored patency. Thus in these patients the four-hour rather than the threehour sample indicated patency. Review of the records showed that the arteriogram had been somewhat delayed in these patients so that in two patients the three-hour blood had been taken five minutes before imaging of the artery (instead of 30 minutes after imaging as intended) whereas in the third patient the blood had been taken only 12 Figure 3 Increase in creatine kinase (CK) activity as % ofpeak in p sustained arterial occlusion atfour hours, in those with restored arterial three andfour hours, and in the three patients with patency at three ho; enzyme activity at three hours was < 20% ofpeak. during sampling period (%) Reinfarction in hospital (%) 6 2 Sustained occlusion (group 3) essed as proportion group 1) or in creatine kinase activity as a result of release from chest wall muscle we examined enzyme activities in relation to defibrillation. Ventricular fibrillation occurred in 10 patients; before entry to the study in one and within four hours of entry in the other nine. Defibrillation without prolonged cardiopulmonary resuscitation was successful in all patients.
Five patients developed ventricular fibrillation in the catheterisation laboratory, in four patients (group 2) at the time that a blocked coronary artery was seen to reopen and in one patient (group 1) shortly before an open infarct related artery was imaged. In all five cases, ventricular fibrillation preceded a rapid rise in enzyme activity, and the arrhythmia was apparently associated with reperfusion. In the other five patients who had occluded arteries at arteriography, no rise in enzymes occurred within two hours of defibrillation, so that the arrhythmia appeared to be associated with persisting coronary occlusion. In no case did it seem that there had been a rise in creatine kinase activity due to release of enzyme from the heart or skeletal muscle as a tesult of defibrillation.
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Of the total group of 318 patients, 241 were men and 77 were women. The mean age was 59 (range 27-75 years) and time from the start of chest pain was 3 0 (range 0-5-6) hours. There were no significant differences in clinical characteristics at entry between the 258 patients who did not have angiography and the 60 patients who did (data not shown). One hundred and ninety one (60%) of the 318 patients had early arterial patency indicated by three hour creatine kinase > 20% of peak, whereas 127 (40%) did not reperfuse early as judged by three hour creatine kinase < 20% of peak. ences between eventual patency rates,9 but the time to peak enzyme release is not a reliable indicator of the timing of reperfusion in individual patients. Use of the rise in total creatine kinase activity at three hours from the start of treatment with streptokinase expressed as a proportion of the peak rise emerges from this study as a simple and reliable marker of patency of the infarct related coronary artery at about 2-5 hours after starting treatment. The three hour normalised value was > 20% of peak in 34/37 patients in whom the infarct related artery was patent (sensitivity 92%) and it was <20% in 21/23 in whom the artery was occluded (specificity 91%). Patients with the clinical syndrome of acute myocardial infarction but a non-diagnostic enzyme rise were correctly identified as having patent infarct related arteries. Moreover, the test remained reliable for patients who had defibrillation without prolonged cardiac resuscitation.
Enzyme activities rise rapidly after reperfusion occurs (fig 3) , so that blood specimens must be taken at strictly defined times (within limits of perhaps 10-15 minutes) to define these changes. The three apparently false negative results in patients with patent arteries (fig 2) in our study were likely because of an unduly short period between attainment of patency and collection of the three-hour blood specimen (the four hour specimens indicating patency). If this is so, the sensitivity of our method could be even higher than 92%.
The clinical relevance of the enzymatic method is supported by results of the prognostic study. The The most important disadvantage both of our method and of the appearance/disappearance model is that the diagnosis of arterial patency in individual patients is necessarily retrospective because the proportion of enzyme release cannot be calculated until the peak value is known. Thus these methods are not applicable for the rapid diagnosis of success or failure of thrombolytic treatment in individual patients. Possible discrepancies between non-invasively diagnosed reperfusion and angiographically defined patency include failure of tissue reperfusion despite restoration of patency of the infarct related artery, reperfusion by collaterals despite persistent occlusion, and uncertainty about angiographic grading of patency, particularly for TIMI 3 v TIMI 2 lesions.'8 Clearly we have insufficient cases in our study to say whether or not such events occur in practice. If they did occur, however, it could be argued that reperfusion diagnosed by the enzymatic method is of greater clinical relevance than recanalisation diagnosed by angiography.
Total creatine kinase is easily measurable, does not deteriorate rapidly with storage at room temperature or from contact with red cells, shows a consistent and accurately quantifiable rise and fall after myocardial infarction,'7 and is sensitive to the effects of therapeutic agents.'9 The method we now describe required 10 blood specimens that were taken without discomfort to the patients from the intravenous line. It would be possible to reduce this number to seven by taking blood at baseline, at three hours and then every four hours from eight to 24 hours for detection of the peak value. At a cost of about 20 p a test for reagents this is a fully automated and cost effective investigation that can be performed in most hospital laboratories.
Although measurement of the cardiac selective creatine kinase MB is favoured by other workers,1213 we think that separation of the 10% or so of cardiac selective activity for assessment of arterial patency in patients with known infarction in whom intramuscular injections are avoided is unnecessary and could in fact diminish sensitivity because of the lower activities that can be measured.
Reduction of cardiac mortality and preservation of left ventricular function for survivors of infarction remain the important goals of thrombolytic treatment. The method we now describe for non-invasive diagnosis of early patency of the infarct related artery correlates both with 30 day mortality and with impairment of left ventricular function, at least for patients with anterior infarction. Early patency of the infarct released artery is clearly an important end point for assessment of thrombolytic efficacy. Randomised clinical trials for testing an increasing number of thrombolytic and adjuvant agents continue to be necessary, but current trials with cardiac mortality as an end point require enrolment of more than 40 000 patients.20 Total creatine kinase activity can be measured easily in any general hospital laboratory, and use of early arterial patency determined by this method could provide meaningful comparisons of different regimens by study of hundreds rather than tens of thousands of patients.
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